title: An analysis of predictors of long-term cadaveric renal allograft survival.
abstract: To determine factors predictive of long-term graft function in patients treated prophylactically with an antilymphocyte antibody, 670 first cadaveric adult renal transplant procedures performed between 1985 and 1991 were reviewed. The actuarial 1- and 5-year patient survival in this group was 95% and 87% respectively, and graft survival was 84% and 70% respectively. The final analysis was based on a study group of 635 patients which excluded 28 patients who lost grafts to early technical failures and 8 patients who were not induced with an antilymphocyte preparation. Multivariate analysis showed that 5-year graft survival was lower in patients with delayed graft function (p = 0.0001), in those who had an acute rejection episode in the first 6 months post-transplant (p = 0.0001), recipients greater than 55 years of age at the time of transplant (p = 0.0001), in patients who were highly sensitized at the time of transplant (p = 0.0331) and, finally, in those who received a graft from an older donor (p = 0.044). The 209 patients with delayed graft function had a 16% lower long-term graft survival than 425 patients with early graft function (62% vs. 78% respectively at 5 years). One or more rejection episodes in the first 6 months post-transplant (329 patients) reduced long-term graft survival by 13% compared to those who did not have a rejection episode (67% vs. 80% respectively at 5 years).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Renal Transplantation Programme, University of Toronto, Ontario, Canada.
authors.forename: E
authors.initials: E
authors.lastname: Cole
authors.forename: D
authors.initials: D
authors.lastname: Naimark
authors.forename: M
authors.initials: M
authors.lastname: Aprile
authors.forename: J
authors.initials: J
authors.lastname: Wade
authors.forename: D
authors.initials: D
authors.lastname: Cattran
authors.forename: Y
authors.initials: Y
authors.lastname: Pei
authors.forename: S
authors.initials: S
authors.lastname: Fenton
authors.forename: M
authors.initials: M
authors.lastname: Robinette
authors.forename: J
authors.initials: J
authors.lastname: Zaltsman
authors.forename: R
authors.initials: R
authors.lastname: Bear
mesh_terms: D000206:Actuarial Analysis; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007114:Immunization; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000473:pathology / Q000502:physiology / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009864:Ontario / Q000453:epidemiology; D012307:Risk Factors; D016019:Survival Analysis; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003404:Creatinine